|
 |
Volume 5, Number 4 (April 2008) | ||||||
Letter from the Editor |
||||||
165 |
What touches us all Wilshire Oncology Medical Group, Inc., La Verne, CA Couldn’t attend the March 13, 2008, ODAC meeting called to address safety concerns about erythropoiesis-stimulating agents? We have a first-hand report from co-editor David H. Henry, MD, 1 of 20 public speakers chosen to address the panel. Couldn’t attend our Third Annual Community Oncology Conference held this past February? We have summaries of the practical information and take-home messages offered in the sessions. All that, and a Community Translations column on preventing oral mucositis.
|
|||||
Community Translations |
||||||
171 |
Calcium phosphate mouth rinse for preventing oral mucositis A new option is now available for a treatment side effect that can be especially difficult for patients—mouth sores. Studies have shown that Caphosol, a supersaturated calcium phosphate rinse, can decrease mucositis and its complications. Along with standard oral care, Caphosol should be initiated at the start of chemotherapy. | |||||
FROM THE COMMUNITY ONCOLOGIST'S PERSPECTIVE Department of Oral Medicine, Tufts University School of Dental Medicine, Boston, MA | ||||||
FROM THE NURSE'S PERSPECTIVE Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, WV
| ||||||
Community Oncology Conference Highlights |
||||||
175 |
Proceedings from the Third Annual Community Oncology Conference More than 300 private practice-based oncologists, hematologists, oncology nurses, pharmacists, and practice administrators convened in Washington, DC, on February 1 and 2, 2008, for the conference. The meeting was designed to reflect the real-world oncology practiced by these clinicians and to address the issues that matter to them. | |||||
Lobbying members of Congress: a political action guide Making your case to a member of Congress may seem like a daunting task, but the director of policy analysis at Community Oncology Alliance took the mystery out of the method. All you need is a little finesse and a lot of persistence.
| ||||||
Crossing the digital Rubicon: incorporating the electronic medical record into your practice It’s time to face the music: electronic medical records are here to stay, so you might as well start singing that tune. And although you may hit some sour notes, in the end you’ll be glad you joined the chorus.
| ||||||
Preventing and managing VTE New guidelines have been developed for the prevention and treatment of VTE in patients with cancer. A major complication of oncologic disease, it is also a leading cause of death in cancer patients.
| ||||||
Pursuing quality care in 2008 Everyone, it seems, is trying to define it and deliver it. So what exactly is quality care, and how do we ensure that every patient receives it? The dialogue takes place here.
| ||||||
Advances in the treatment of HER2+ breast cancer It’s one of the strengths of Community Oncology: viewing a clinical issue from the perspective of the physician, the nurse, and the practice administrator. In this case, we take a multidisciplinary look at treatment for HER2+ breast cancer.
| ||||||
Payers and providers: a love match? It’s one of the strengths of Community Oncology: viewing a clinical issue from the perspective of the physician, the nurse, and the practice administrator. In this case, we take a multidisciplinary look at treatment for HER2+ breast cancer.
| ||||||
Managing toxicities of EGFR inhibitors How do you explain to patients that a side effect is a good thing? In the case of EGFR inhibitors, it appears to be true. We take a multidisciplinary look at treatment with this class of drugs and offer some practical suggestions for helping patients cope with their toxicities.
| ||||||
Incorporating genetic testing and counseling in your practice Of the 2,000 certified genetic counselors in the United States, there may be as few as 700 who focus on cancer. But genetic testing and counseling are in increasing demand. Here’s how to include them in your practice.
| ||||||
Novel agents changing the outlook for renal cell carcinoma The rapidity with which new agents have become available to treat renal cell carcinoma is almost dizzying. Here to sort it all out is a multidisciplinary team from a single practice in Bethlehem, Pennsylvania.
| ||||||
Washington Update |
||||||
211 |
Talking to ODAC and meeting a stone wall Pennsylvania Hospital, Philadelphia, PA Could the ODAC members have been less equipped to deal with the questions of ESAs? According to our eyewitness, the thoughtful presentations to ODAC were lost on most of the panel. | |||||
PATIENT GUIDE Until the ODAC-recommended consent form becomes available, we offer this evidence-based fact sheet to help you educate your patients. | ||||||
VIEWPOINT Community Oncology Alliance The executive director of the Community Oncology Alliance worries that the government is trying to tie the hands of clinicians.
| ||||||
© 2008 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||||
46 kb